We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more
Mz8.5
Meso-Zeaxanthin Research
Likely helpsHigh safety
38 peer-reviewed studies
What the evidence says
Likely helps
Meso-Zeaxanthin appears to help in 3 of 3 studies with measurable effects — the evidence leans clearly favourable.
Most evidence is from high-quality meta-analyses and randomised trials published 2011–2024 with a typical study size of 63 participants.
Based on 38 studies · 3 meta-analyses · 22 RCTs · 7,611 total participants
Confidence
High
What the studies found
3helped· 35 more without graded effect data
By outcome
Vision & macular pigmentEnhanced macular protection and reduced glare sensitivity within 3-6 months · 3-6 months
Likely helps35 studies
Cognitive function
Mostly mechanism / observational22 studies
Neuroprotection & brain aging
Mostly mechanism / observational7 studies
Therapeutic & clinical
Mostly mechanism / observational6 studies
Inflammation
Mostly mechanism / observational3 studies
Heart & blood pressure
Too few graded studies1 study
Anxiety & stress
Too few graded studies1 study
Women's health
Too few graded studies1 study
Safety profile
Too few graded studies1 study
By the numbers
Pulled from 20 studies with measurable effects
Likely real effects
75%
across studies
People studied
7,611
typical study: 63 people
Strongest designs
25
3 pooled, 22 randomised
Showed benefit
100%
3/3 studies
How long studies ran
1–3 months
2
3+ months
4
Populations Studied
General population3
Subjects with and without age-related macular degeneration2
Adults with healthy eyes (mean age 43 years)1
Glaucomatous patients1
Active research area
15 studies in the last 5 years · Latest meta-analysis: 2024
201120172024
1Meta-AnalysisCited 8×n=3,159 · very large study2024
All intervention groups including L+Z+MZ significantly increased MPOD compared to placebo.
2Macular pigment optical densityMeta-AnalysisCited 54×n=3,189 · very large study2021
Our objective was to determine a minimum concentration of lutein/zeaxanthin intake that is associated with a statistically significant and/or clinically important change in macular pigment optical ...
Wilson LM et al. · Advances in nutrition (Bethesda, Md.) (2021)
Noticeable benefit
← WorseNo effectBetter →
Our objective was to determine a minimum concentration of lutein/zeaxanthin intake that is associated with a statistically significant and/or clinically important change in macular pigment optical density (MPOD) among adults with healthy eyes.
We included 46 studies (N = 3189 participants; mean age = 43 y; 42% male).
There was no statistically significant change in MPOD among studies evaluating <5 mg/d of total lutein/zeaxanthin intake which primarily assessed dietary interventions for 3-6 mo (pooled mean difference, 0.02; 95% CI: -0.01 to 0.05).
Arunkumar R et al. · Advances in experimental medicine and biology (2023)
The pyridinium bisretinoid, N-retinylidene-N-retinylethanolamine (A2E), contributes to drusen formation in dry age-related macular degeneration (AMD) and to the autofluorescent flecks in autosomal recessive Stargardt disease (STGD1).
Retinal carotenoids attenuate A2E formation and can directly and indirectly alleviate A2E-mediated oxidative damage.
In this chapter, we review these more recently recognized interconnections between MP carotenoids and A2E bisretinoids.
The data suggest that carotenoid vitamin therapy exerts synergic neuroprotective benefits and has the capacity to serve adjunctive therapy in the management of glaucoma.
Lem DW et al. · Nutrients (2021)
A comprehensive literature search was conducted in three databases (PubMed, Cochrane Library, and Web of Science) and 20 records were identified for screening.
Lutein demonstrated enhanced neuroprotection on retinal ganglion cell survival and preserved synaptic activity.
In clinical studies, a protective trend was seen with greater dietary consumption of carotenoids and risk of glaucoma, while greater carotenoid levels in macular pigment were largely associated with improved visual performance in glaucomatous eyes.
These findings provide a strong molecular basis and a line of evidence that suggests carotenoid vitamin therapy may offer enhanced neuroprotective effects with therapeutic potential to function as an adjunct nutraceutical strategy for management of diabetic retinopathy.
Lem DW et al. · Nutrients (2021)
Lutein and zeaxanthin demonstrated significant protection against capillary cell degeneration and hyperglycemia-induced changes in retinal vasculature.
Observational studies indicate that depletion of xanthophyll carotenoids in the macula may represent a novel feature of DR, specifically in patients with type 2 or poorly managed type 1 diabetes.
Meanwhile, early interventional trials with dietary carotenoid supplementation show promise in improving their levels in serum and macular pigments concomitant with benefits in visual performance.
Intraretinal levels of these carotenoids are inversely associated with the risk of age-related macular degeneration (AMD), and oral supplementation with these carotenoids can significantly reduce A...
Li B et al. · Methods in enzymology (2022)
Intraretinal levels of these carotenoids are inversely associated with the risk of age-related macular degeneration (AMD), and oral supplementation with these carotenoids can significantly reduce AMD risk.
We first introduce carotenoid extraction methods from the retina, retinal pigment epithelium (RPE)/choroid, serum, and liver of the human and animal models, such as mice and Japanese quails, as well as from algae, bacteria, and chicken egg yolks and cultured cells.
We then review macular carotenoid detection by spectroscopy and HPLC, while particularly introducing carotenoid separation via cyano columns, chiral columns, and C30 columns.
Dietary lutein and zeaxanthin intake increased MPOD in six of the seven clinical trials and significantly improved most of the cognitive functions studied.
García-Romera MC et al. · Physiology & behavior (2022)
Dietary lutein and zeaxanthin intake increased MPOD in six of the seven clinical trials and significantly improved most of the cognitive functions studied.
Brain activity also was related to MPOD, but the results were inconsistent.
Only four of the eleven observational studies were based on young people and all studies showed a significant relationship between MPOD and cognitive functions.
This meta-analysis revealed that lutein, zeaxanthin and meso-zeaxanthin supplementation improved MPOD both in AMD patients and healthy subjects with a dose-response relationship.
Ma L et al. · Nutrients (2016)
Noticeable benefit
← WorseNo effectBetter →
Xanthophyll carotenoids supplementation was associated with significant increase in MPOD in AMD patients (WMD, 0.07; 95% CI, 0.03 to 0.11) and healthy subjects (WMD, 0.09; 95% CI, 0.05 to 0.14).
Additionally, the changes in MPOD were related with baseline MPOD levels (rAMD = -0.43, p = 0.06; rhealthy subjects = -0.71, p < 0.001) and blood xanthophyll carotenoids concentration (rAMD = 0.40, p = 0.07; rhealthy subjects = 0.33, p = 0.05).
Stratified analysis showed a greater increase in MPOD among trials supplemented and combined with meso-zeaxanthin.
The MP carotenoids filter high-intensity, short-wavelength visible light and are powerful antioxidants in a region vulnerable to light-induced oxidative stress.
Arunkumar R et al. · Biochimica et biophysica acta. Molecular and cell biology of lipids (2020)
The MP carotenoids filter high-intensity, short-wavelength visible light and are powerful antioxidants in a region vulnerable to light-induced oxidative stress.
This review focuses on MP chemistry, absorption, metabolism, transport, and distribution with special emphasis on animal models used for MP study.
This article is part of a Special Issue entitled Carotenoids recent advances in cell and molecular biology edited by Johannes von Lintig and Loredana Quadro.
In this review, we discuss how the differences in the specific properties of lutein and zeaxanthin could help explain the preferential accumulation of zeaxanthin in the most vulnerable region of the macula.
Widomska J et al. · Nutrients (2020)
Zeaxanthin concentrations are 2.5-fold higher than lutein in the cone-dense central fovea.
This is an ~20-fold increase in the molar ratio relative to eccentric retinal regions with biochemically detectable macular xanthophylls.
The distribution of diet-based macular xanthophylls and the lutein metabolite meso-zeaxanthin varies considerably by retinal eccentricity.
The question of an optimal dietary antioxidant supply is evaluated in the context of the dual roles of both oxidants and antioxidants, in all vital functions of living organisms, and the profound impact of individual and environmental context.
Demmig-Adams B et al. · Molecules (Basel, Switzerland) (2020)
This review compares and contrasts the role of carotenoids across the taxa of life-with a focus on the xanthophyll zeaxanthin (and its structural isomer lutein) in plants and humans.
Xanthophylls' multiple protective roles are summarized, with attention to the similarities and differences in the roles of zeaxanthin and lutein in plants versus animals, as well as the role of meso-zeaxanthin in humans.
Detail is provided on the unique control of zeaxanthin function in photosynthesis, that results in its limited availability in leafy vegetables and the human diet.
Next, we turn to clinical evidence supporting functional benefits of these carotenoids in normal eyes and for their potential protective actions against ocular disease from infancy to old age.
Bernstein PS et al. · Progress in retinal and eye research (2016)
Next, we turn to clinical evidence supporting functional benefits of these carotenoids in normal eyes and for their potential protective actions against ocular disease from infancy to old age.
15Lutein and zeaxanthin statusSystematic ReviewCited 126×2016
Accumulating evidence about variable interindividual response to dietary intake of these carotenoids, based on genetic or metabolic influences, suggests that there may be subgroups that benefit from higher levels of intake and/or alternate strategies to improve lutein and zeaxanthin status.
Mares J · Annual review of nutrition (2016)
Additionally, egg yolks and human milk appear to be bioavailable sources.
The prevalence of lutein, zeaxanthin, and meso-zeaxanthin in supplements is increasing.
Setting optimal and safe ranges of intake requires additional research, particularly in pregnant and lactating women.
Our data show that L, Z, & MZ supplementation results in decreased serum IL-1β, TNF-α, and OxLDL.
Stringham NT et al. · Nutrition, metabolism, and cardiovascular diseases : NMCD (2024)
Our data show that L, Z, & MZ supplementation results in decreased serum IL-1β, TNF-α, and OxLDL.
This suggests that these carotenoids are acting systemically to attenuate oxidative lipid products and inflammation, thus reducing their contribution to atherosclerotic plaque formation.
Antioxidant supplementation in patients with nonadvanced age-related macular degeneration results in significant increases in macular pigment and improvements in CS and other measures of visual function. (Clinical trial, http://www.isrctn.com/ISRCTN13894787).
Akuffo KO et al. · Investigative ophthalmology & visual science (2017)
There was a statistically significant improvement in the primary outcome measure (letter CS at 6 cycles per degree [6 cpd]) over time (P = 0.013), and this observed improvement was statistically comparable between interventions (P = 0.881).
Statistically significant increases in macular pigment at all eccentricities were observed over time (P < 0.0005, for all), and the degree of augmentation was statistically comparable between interventions (P > 0.05).
Antioxidant supplementation in patients with nonadvanced age-related macular degeneration results in significant increases in macular pigment and improvements in CS and other measures of visual function. (Clinical trial, http://www.isrctn.com/ISRCTN13894787).
This randomized, double-blind, placebo-controlled clinical trial demonstrates a memory-enhancing effect of daily supplementation with L, Z, and MZ in healthy subjects with low MP at baseline.
Power R et al. · Journal of Alzheimer's disease : JAD (2018)
Following 12-month supplementation, individuals in the active group exhibited statistically significant improvements in memory when compared to the placebo group (paired associated learning [PAL] memory score [rANOVA, p = 0.009]; PAL errors [rANOVA, p = 0.017]).
This randomized, double-blind, placebo-controlled clinical trial demonstrates a memory-enhancing effect of daily supplementation with L, Z, and MZ in healthy subjects with low MP at baseline.
The implications of these findings for intellectual performance throughout life, and for risk of cognitive decline in later life, warrant further study.
These results support a biologically plausible rationale whereby these nutrients work synergistically, and in a dose-dependent manner, to improve working memory in cognitively healthy older adults.
Power R et al. · Clinical nutrition (Edinburgh, Scotland) (2022)
Statistically significant improvements in tissue carotenoid concentrations, serum xanthophyll carotenoid concentrations and plasma ω-3FA concentrations were also observed in the active group versus placebo (point estimate effect sizes ranged 0.078-0.589).
These results support a biologically plausible rationale whereby these nutrients work synergistically, and in a dose-dependent manner, to improve working memory in cognitively healthy older adults.
Increasing nutritional intake of carotenoids and ω-3FAs may prove beneficial in reducing cognitive decline and dementia risk in later life.